Navigation Links
Digirad Corporation Appoints John W. Sayward to Its Board of Directors
Date:3/19/2008

POWAY, Calif., March 19 /PRNewswire-FirstCall/ -- Digirad Corporation (Nasdaq: DRAD), a leading provider of medical diagnostic imaging products and services to physicians' offices, hospitals and imaging centers, today announced its board of directors has appointed veteran healthcare executive John W. Sayward director and audit committee chairman, effective immediately.

Mr. Sayward, 56, has more than 30 years of finance, accounting, operational and administrative experience in the healthcare industry, and has previously served on the board of a public pharmaceuticals company. He replaces Raymond Dittamore, 65, who resigned from the board and has retired from business. Mr. Dittamore joined the Digirad board in March 2004 and served as chairman of the audit committee.

Digirad Chairman R. King Nelson said, "John Sayward's extensive operational and financial management background in healthcare and his experience in cardiology will be valuable assets to Digirad as the Company moves forward with its Centers of Excellence expansion strategy and focuses on accelerating its top and bottom line growth.

"We would also like to thank Ray for his many years of providing solid guidance and support of Digirad, and we wish him the very best," King added.

From September 2005 to January 2007, Mr. Sayward was a partner at Nippon Heart Hospital, LLC (NHH), a healthcare management company, formed to partner with leading cardiologists to improve cardiovascular care and build and manage cardiovascular-care hospitals in Japan. While at NHH, Mr. Sayward helped develop relationships with cardiology leaders, government officials and hospital administrators, managed NHH's strategic business plan and evaluated alternatives for financing that plan. From 2002 to 2005, he was executive vice president and chief financial officer of LMA North America Inc., a medical device company, where he managed the company's operations, quality and human resources functions and was a key player in the company's initial public offering.

Prior to 2002, he was chief financial officer and a director of SICOR, Inc., a $2.5 billion pharmaceuticals company that was acquired by Teva Pharmaceuticals. As a senior executive at SICOR he made significant contributions to a highly successful business turnaround and managed a number of corporate-level transactions including the divestiture of a subsidiary, an acquisition and secured financing for strategic expansion.

Mr. Sayward received his undergraduate degree from Northwestern University and a master of management degree from Kellogg School of Management at Northwestern University.

About Digirad Corporation

Digirad provides diagnostic medical imaging products and services to physicians' offices, hospitals and imaging centers for cardiac, vascular, and general imaging applications. Digirad's Cardius XPO line of nuclear imaging cameras use patented solid-state technology and unique multi (single, dual, triple) head design for superior performance and advanced features for sharper digital images, faster processing, compact size, lighter weight for portability, ability to handle patients up to 500 pounds, and improved patient comfort compared to standard nuclear cameras. Digirad's 2020tc general-purpose nuclear imager has a small footprint and may also be configured for fixed or mobile use to supplement primary imaging. Digirad's installed base of equipment exceeds 450 systems; in addition, a mobile fleet of more than 120 nuclear and ultrasound imaging systems is being used in 22 states, primarily in the eastern, midwestern and southwestern United States. For more information, please visit http://www.digirad.com. Digirad(R), Digirad Imaging Solutions(R), and Cardius(R) are registered trademarks of Digirad Corporation.

Forward-Looking Statements

Digirad cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. You can identify these statements by the fact that they do not relate strictly to historical or current facts and use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" and other words and terms of similar meaning in connection with a discussion of future operating or financial performance or events. Examples of such statements include statements regarding the Company's centers of influence expansion strategy and top and bottom line growth projections. The inclusion of these and other forward-looking statements should not be regarded as a representation by Digirad that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Digirad's business, market conditions, overall business prospects and operations; and other risks detailed in Digirad's filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Form 8-K and other reports. Given these uncertainties, readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Digirad undertakes no obligation to revise or update this press release including the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Investor Contact: Company Contact:

Dan Matsui Mark Casner

Allen & Caron CEO

949-474-4300 858-726-1600

d.matsui@allencaron.com ir@digirad.com


'/>"/>
SOURCE Digirad Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Digirad Corporation to Release Third Quarter, Nine-Month Financial Results on October 25, 2007
2. Digirad Corporation Named to Deloitte Technology Fast 50
3. Digirad Reports 2007 Third-Quarter, Nine-Month Financial Results
4. Digirad Corporation and The Methodist Hospital in Houston Sign Letter of Agreement
5. Digirad Corporation Board of Directors Appoints R. King Nelson Chairman
6. Digirad to Introduce New Clinical Standard for Cardiac SPECT
7. Digirad Corporation to Release Fourth Quarter, Year-End Financial Results on February 7, 2008
8. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
9. Brooke Franchise Corporation Announces Selected July Results
10. MedThink Communications Retained by NanoBio Corporation
11. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... According to the American Cancer Society , ... more than 95%. Once the cancer spreads to other organs, bones, or lymph nodes, ... how to avoid this latter group, tune in to Lifestyle Magazine on ...
(Date:3/27/2017)... ... March 27, 2017 , ... Sodium determination ... are complicated and require expert user knowledge. In a live webinar on April ... the simplified, yet highly accurate, determination of sodium. , It has long been ...
(Date:3/27/2017)... Irvine, CA (PRWEB) , ... March 27, 2017 ... ... company has entered a settlement agreement to resolve the pending litigation between itself ... Court for the District of Utah). , “I am thrilled to announce that ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... deaths soared 167%,(1) with opioids alone responsible for over 33,000 of the 52,404 ... has sponsored Assembly Bill (AB) 1512, which proposes a tax on prescription opioids ...
(Date:3/27/2017)... , ... March 27, 2017 , ... Harris Communications, Inc., ... hearing, is bringing its latest products to the Deaf Seniors of America Conference, April ... the opportunity to meet with knowledgeable ASL friendly staff from Harris Communications and to ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... DUBLIN , Mar. 24, 2017 Research and ... (IPF) Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with ... Corporation, Merck & Co., Inc., Biogen and Sanofi are involved in the ... candidates, of which one is in Phase III stage, 15 are in ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Microplate Instrumentation ... ... comprehensive analytics for the US, Canada , ... , Latin America , and Rest of World. Annual ... a six-year historic analysis is provided for these markets. Market data and ...
(Date:3/24/2017)... 23, 2017  Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... clinical-stage oncology and dermatology biopharmaceutical company, today disclosed ... Term Sheet (the "Definitive Financing") it entered into ... Company,s stockholders, who are referred to in the ... 8-K filed with the Securities and Exchange Commission. ...
Breaking Medicine Technology: